Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells

Immune checkpoint inhibitor (ICI) clinically benefits cancer treatment. However, the ICI responses are only achieved in a subset of patients, and the underlying mechanisms of the limited response remain unclear. 160 patients with non‐small cell lung cancer treated with anti‐programmed cell death pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Se‐Hoon, Kim, Yeongmin, Jeon, Bu‐Nam, Kim, Gihyeon, Sohn, Jinyoung, Yoon, Youngmin, Kim, Sujeong, Kim, Yunjae, Kim, Hyemin, Cha, Hongui, Lee, Na‐Eun, Yang, Hyunsuk, Chung, Joo‐Yeon, Jeong, A‐Reum, Kim, Yun Yeon, Kim, Sang Gyun, Seo, Yeonhee, Park, Sehhoon, Jung, Hyun Ae, Sun, Jong‐Mu, Ahn, Jin Seok, Ahn, Myung‐Ju, Park, Hansoo, Yoon, Kyoung Wan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265102/
https://www.ncbi.nlm.nih.gov/pubmed/37097643
http://dx.doi.org/10.1002/advs.202204378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265102/
https://www.ncbi.nlm.nih.gov/pubmed/37097643
http://dx.doi.org/10.1002/advs.202204378

Ejemplares similares